Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00372489 · ClinicalTrials.gov registry record · Phase 2
Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD
A Phase 2 study, sponsored by Affymax.
- Terminated
- Registry status
- Phase 2
- Development phase
- 81
- Enrollment target
NCT00372489 is a Phase 2 study that was terminated before completion, run by Affymax. The registered enrollment target is 81 participants.
The verdict
NCT00372489, a Phase 2 study, was terminated before completion, sponsored by Affymax.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 81 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the long term safety and tolerability of peginesatide for the maintenance of hemoglobin in participants with chronic kidney disease (CKD) who had received at least 24 weeks of peginesatide treatment in an earlier study.
Interventions
- DRUG peginesatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2006-09 |
| Est. Completion | 2009-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00372489
The ClinicalTrials.gov registry entry for NCT00372489 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Affymax, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which peginesatide is the first listed.
NCT00372489 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00372489 about?
NCT00372489 is a clinical study titled "Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD". The purpose of this study was to evaluate the long term safety and tolerability of peginesatide for the maintenance of hemoglobin in participants with chronic kidney disease (CKD) who had received at least 24 weeks of peginesatide treatment in an earlier study.
What is the current status of trial NCT00372489?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 81 participants. The study started on 2006-09. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00372489?
The interventions under investigation include: peginesatide (DRUG).
Who is sponsoring clinical trial NCT00372489?
This trial is sponsored by Affymax, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.